PreprintCited by 209CRISPR and Genetic EngineeringRNA regulation and diseaseRNA Interference and Gene Delivery

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq

Open access

Abstract

We present multiplex Digenome-seq to profile genome-wide specificities of up to 11 CRISPR-Cas9 nucleases simultaneously, saving time and reducing cost. Cell-free human genomic DNA was digested using multiple sgRNAs combined with the Cas9 protein and then subjected to whole-genome sequencing. In vitro cleavage patterns, characteristic of on- and off-target sites, were computationally identified across the genome using a new DNA cleavage scoring system. We found that many false-positive, bulge-type off-target sites were cleaved by sgRNAs transcribed from an oligonucleotide duplex but not by those transcribed from a plasmid template. Multiplex Digenome-seq captured many bona fide off-target sites, missed by other genome-wide methods, at which indels were induced at frequencies <0.1%. After analyzing 964 sites cleaved in vitro by these sgRNAs and measuring indel frequencies at hundreds of off-target sites in cells, we propose a guideline for the choice of target sites for minimizing CRISPR-Cas9 off-target effects in the human genome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gr.199588.115

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Improving Digenome-seq analysis. (A) Genome-wide Circos plots of in vitro DNA cleavage scores. Human genomic DNA (red) or RGEN-digested genomic DNA (green) was subjected to whole-genome sequencing. The few false-positive sites found in intact genomic DNA are not visible because their cleavage scores are not high. (B) Schematic overview of Digenome-seq using sgRNA transcribed from an oligonucleotide duplex or a plasmid. (C) Sequence logos of cleavage sites obtained using sgRNA transcribed from an oligonucleotide duplex or a plasmid.
Figure 1. Improving Digenome-seq analysis. (A) Genome-wide Circos plots of in vitro DNA cleavage scores. Human genomic DNA (red) or RGEN-digested genomic DNA (green) was subjected to whole-genome sequencing. The few false-positive sites found in intact genomic DNA are not visible because their cleavage scores are not high. (B) Schematic overview of Digenome-seq using sgRNA transcribed from an oligonucleotide duplex or a plasmid. (C) Sequence logos of cleavage sites obtained using sgRNA transcribed from an oligonucleotide duplex or a plasmid.CC BY-NC · PubMed Central
Figure 2. Multiplex Digenome-seq. (A) Schematic overview of multiplex Digenome-seq. (B) A Venn diagram showing the number of in vitro cleavage sites captured by monoplex and multiplex Digenom-seq analyses. (C) In vitro DNA cleavage scores across Chromosome X obtained by monoplex or multiplex Digenome-seq.
Figure 2. Multiplex Digenome-seq. (A) Schematic overview of multiplex Digenome-seq. (B) A Venn diagram showing the number of in vitro cleavage sites captured by monoplex and multiplex Digenom-seq analyses. (C) In vitro DNA cleavage scores across Chromosome X obtained by monoplex or multiplex Digenome-seq.CC BY-NC · PubMed Central
Figure 3. Analysis of multiplex Digenome-captured sites. (A) Venn diagrams showing the number of sites captured by Digenome-seq, GUIDE-seq, and HTGTS. (B) Fractions of sites captured by Digenome-seq according to the total mismatch number (top) and the mismatch number in the seed region (bottom). (C, top) Scatterplot of the number of sites with six or fewer mismatches in the human genome versus the number of Digenome-captured sites. (Bottom) Eleven RGEN target sites were divided into two groups, G1 and G2 (those with fewer than 13,000 and 16,000 sites, respectively, harboring six or fewer mismatches in the human genome). Error bars, SEM. The P-value was calculated by Student's t-test. (D) Scatterplot of the number of GUIDE-seq captured sites versus the number of Digenome-seq captured sites.
Figure 3. Analysis of multiplex Digenome-captured sites. (A) Venn diagrams showing the number of sites captured by Digenome-seq, GUIDE-seq, and HTGTS. (B) Fractions of sites captured by Digenome-seq according to the total mismatch number (top) and the mismatch number in the seed region (bottom). (C, top) Scatterplot of the number of sites with six or fewer mismatches in the human genome versus the number of Digenome-captured sites. (Bottom) Eleven RGEN target sites were divided into two groups, G1 and G2 (those with fewer than 13,000 and 16,000 sites, respectively, harboring six or fewer mismatches in the human genome). Error bars, SEM. The P-value was calculated by Student's t-test. (D) Scatterplot of the number of GUIDE-seq captured sites versus the number of Digenome-seq captured sites.CC BY-NC · PubMed Central
Figure 4. Indel frequencies determined using targeted deep sequencing at off-target sites. (A) Schematic of conventional sgRNAs (GX19 sgRNA) and modified sgRNAs (ggX20 sgRNA). Indel frequencies at NGS-validated on- and off-target sites for the EMX1 (B), HEK293-3 (C), and RNF2 sgRNAs (D). Specificity ratios calculated by dividing the indel frequency at the on-target site with that at an off-target site for the EMX1 (E), HEK293-3 (F), and RNF2 sgRNAs (G).
Figure 4. Indel frequencies determined using targeted deep sequencing at off-target sites. (A) Schematic of conventional sgRNAs (GX19 sgRNA) and modified sgRNAs (ggX20 sgRNA). Indel frequencies at NGS-validated on- and off-target sites for the EMX1 (B), HEK293-3 (C), and RNF2 sgRNAs (D). Specificity ratios calculated by dividing the indel frequency at the on-target site with that at an off-target site for the EMX1 (E), HEK293-3 (F), and RNF2 sgRNAs (G).CC BY-NC · PubMed Central
Figure 5. Analysis of NGS-validated and NGS-invalidated off-target sites. Plots of relative indel frequencies (log scale) at off-target sites harboring the number of mismatches indicated in the entire 20-nt sequence (A) or the 10-nt seed sequence (B,C). NGS-tested sites (A) were divided into two groups: validated sites (B) and invalidated sites (C). NGS-validated sites and NGS-invalidated sites were those with indel frequencies above and below, respectively, noise indel levels.
Figure 5. Analysis of NGS-validated and NGS-invalidated off-target sites. Plots of relative indel frequencies (log scale) at off-target sites harboring the number of mismatches indicated in the entire 20-nt sequence (A) or the 10-nt seed sequence (B,C). NGS-tested sites (A) were divided into two groups: validated sites (B) and invalidated sites (C). NGS-validated sites and NGS-invalidated sites were those with indel frequencies above and below, respectively, noise indel levels.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

Sorted by citations

Metadata

Authors
Kim, D., Kim, S., Kim, S., Park, J., & Kim, J.-S.
Affiliations
  • Seoul National University (KR)
  • Hanyang University (KR)
Venue
Genome Research
Published
2016-01-19
Volume
26
Issue
3
Pages
406-415
ISSN
  • 1088-9051 (ISSN-L)
  • 1549-5469
OpenAlex
W2273244674
Cited by
208
References
37
Citations by year
2026: 8 · 2025: 15 · 2024: 13 · 2023: 12 · 2022: 17 · 2021: 23 · 2020: 29 · 2019: 22 · 2018: 26 · 2017: 21 · 2016: 22
Type
posted content
Language
en
Open access
Locations
  • Genome Research (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
IBS (IBS-R021-D1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
CRISPR/Cas9, off-target effects, single guide RNA, indel frequency, target site selection, genome editing
MeSH terms
Binding Sites, Humans, Protein Binding, Reproducibility of Results, Genome, Human, Gene Targeting, Genomics, INDEL Mutation, Position-Specific Scoring Matrices, High-Throughput Nucleotide Sequencing, Nucleotide Motifs, Mutation Rate, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review